SELECTIVE ACTIVATION OF RAS ONCOGENES IN FOLLICULAR AND UNDIFFERENTIATED THYROID CARCINOMAS

被引：105

作者：

MANENTI, G ^{[1
]}

PILOTTI, S ^{[1
]}

RE, FC ^{[1
]}

DELLAPORTA, G ^{[1
]}

PIEROTTI, MA ^{[1
]}

机构：

[1] IST NAZL TUMORI,DIV ANAT PATOL & CITOL,I-20133 MILAN,ITALY

来源：

EUROPEAN JOURNAL OF CANCER | 1994年 / 30A卷 / 07期

关键词：

POLYMERASE CHAIN REACTION; DNA MUTATIONAL ANALYSIS; OLIGONUCLEOTIDE PROBES; GENES; RAS; THYROID NEOPLASMS; NEOPLASM METASTASES; PROGNOSIS;

D O I：

10.1016/0959-8049(94)90130-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A total of 96 tumour samples (88 primary tumours and 8 nodal metastases) from 88 patients with thyroid adenomas and carcinomas were investigated for ras gene mutations using polymerase chain reaction, oligonucleotide probing and sequencing. Neither the 19 adenomas nor the 31 papillary carcinomas analysed harboured point mutations. In our cases, mutations in all three ras oncogenes were found in follicular carcinomas (five out of 21) and in the less differentiated thyroid tumour: poorly differentiated carcinomas (three out of 11) and undifferentiated carcinomas (one out of five). Finally, mutated ras oncogenes had a significant association with the appearance of haematogenous (particularly bone) metastases, suggesting a role of ras genes activation in the metastatic capability of these tumours.

引用

页码：987 / 993

页数：7

共 39 条

[21]

Maniatis T., 1982, MOL CLONING

[22] PAPILLARY THYROID-CARCINOMA IN KANAZAWA, JAPAN - PROGNOSTIC-SIGNIFICANCE OF HISTOLOGICAL SUBTYPES [J].

MIZUKAMI, Y ;

NOGUCHI, M ;

MICHIGISHI, T ;

NONOMURA, A ;

HASHIMOTO, T ;

OTAKE, S ;

NAKAMURA, S ;

MATSUBARA, F .

HISTOPATHOLOGY, 1992, 20 (03) :243-250

[23] POINT MUTATIONS OF RAS ONCOGENES ARE AN EARLY EVENT IN THYROID TUMORIGENESIS [J].

NAMBA, H ;

RUBIN, SA ;

FAGIN, JA .

MOLECULAR ENDOCRINOLOGY, 1990, 4 (10) :1474-1479

[24] ANALYSIS OF RAS ONCOGENE MUTATIONS IN HUMAN LYMPHOID MALIGNANCIES [J].

NERI, A ;

KNOWLES, DM ;

GRECO, A ;

MCCORMICK, F ;

DALLAFAVERA, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (23) :9268-9272

[25]

ROCHLITZ CF, 1989, CANCER RES, V49, P357

[26]

SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO

[27]

2-X

[28] RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE [J].

SANTORO, M ;

CARLOMAGNO, F ;

HAY, ID ;

HERRMANN, MA ;

GRIECO, M ;

MELILLO, R ;

PIEROTTI, MA ;

BONGARZONE, I ;

DELLAPORTA, G ;

BERGER, N ;

PEIX, JL ;

PAULIN, C ;

FABIEN, N ;

VECCHIO, G ;

JENKINS, RB ;

FUSCO, A .

JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (05) :1517-1522

[29]

SHI YF, 1991, CANCER RES, V51, P2690

[30] K-RAS ONCOGENE ACTIVATION AS A PROGNOSTIC MARKER IN ADENOCARCINOMA OF THE LUNG [J].

SLEBOS, RJC ;

KIBBELAAR, RE ;

DALESIO, O ;

KOOISTRA, A ;

STAM, J ;

MEIJER, CJLM ;

WAGENAAR, SS ;

VANDERSCHUEREN, RGJRA ;

VANZANDWIJK, N ;

MOOI, WJ ;

BOS, JL ;

RODENHUIS, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (09) :561-565

← 1 2 3 4 →